The efficiency of several selective inhibitors towards the PI3K-Akt-mTOR pathway has been studied in AML cell lines and primary AML cells, and results have shown that Akt can be reactivated through negative feedback mechanisms subsequent to rapamycin-mediated mTOR inhibition. The gene discussed is PIK3CD; the disease is acute myeloid leukemia.